AMAG Ferumoxytol Avoids Safety Concerns Seen With Luitpold’s Injectafer
Approval of AMAG Pharmaceuticals' anemia candidate ferumoxytol will probably not be impeded by unattributable safety issues that may resign Luitpold's Injectafer to second-line use
You may also be interested in...
Luitpold's Injectafer should be reserved for second-line use for treatment of iron deficiency anemia in postpartum patients and those with heavy uterine bleeding, FDA's Drug Safety and Risk Management Advisory Committee recommended Feb. 1
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf